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PreviewsStem Cells for Lung Cancer?
Stem cells are believed to be crucial players in tumor
development. There is much interest in identifying
those compartments that harbor stem cells involved
in lung cancer, given the high incidence and recur-
rence rate of this disease. In this issue of Cell, Kim
and colleagues describe a niche in the bronchioal-
veolar duct junction of adult mouse lung that harbors
stem cells from which adenocarcinomas are likely to
arise (Kim et al., 2005). They enriched, propagated,
and differentiated these stem cells in vitro and found
that they were activated by the oncogenic protein
K-ras. This study provides exciting insights into how
the stem cell compartment operates during both nor-
mal lung-tissue homeostasis and the development of
lung cancer. The new work offers perspectives on
possible therapeutic interventions to combat lung
cancer.
A key characteristic of stem cells is their capacity for
self-renewal. A normal cell must have the capacity to
self-renew in order to acquire a sufficient number of
mutations to enable transformation into a cancer cell.
The accumulation of deleterious mutations takes place
only in cells that already have the capacity for self-
renewal or that acquire this property early in the tumori-
genic process. Examples of both these situations have
been reported recently in tumors of the hematopoietic
system (Bonnet and Dick, 1997; Jamieson et al., 2004).
Usually, a subset of cells in a tumor exhibit this self-
renewal capacity and regenerate the tumor when seri-
ally grafted into recipient animals; in contrast, other,
often more differentiated, tumor cells lack this capacity.
Cells with tumor regenerating capacity have been
called “cancer stem cells” (CSCs; Pardal et al., 2003).
The importance of CSCs in tumorigenesis has been
demonstrated for several tumor types. An important
criterion of CSCs is that they enable serial propagation
of tumors that retain the often diverse marker profile of
the primary tumor (Singh et al., 2004).
If CSCs are the driving force of tumor formation, then
therapeutic interventions that target the main tumor
mass but not the CSCs are bound to fail or, at best,
leave the patient at risk of cancer recurrence. Lung can-
cer is a good example of this conundrum. This disease
is responsible for 30% of all cancer deaths worldwide
and cure rates are disappointingly low due to drug-
refractory recurrent disease. As tumors are usually de-
tected late in disease progression, we lack insight into
the early stages of tumorigenesis and knowledge about
the target cells in which the deleterious mutations ac-
cumulate. This insight has to come from animal models
that closely mimic the human disease.
In the rodent lung, there are several stem cell niches
that are key in maintaining the epithelial layers of lung
tissue (Giangreco et al., 2002; Hong et al., 2004; Reyn-
olds et al., 2000). Progenitors of bronchiolar Clara cells(a type of epithelial cell found in the distal lung) are
crucial for the renewal of bronchial, bronchiolar, and al-
veolar epithelia. This was demonstrated by ablating
Clara cell progenitors in mouse lung using Gancyclovir
treatment of transgenic mice expressing HSV-TK driven
by a Clara cell-specific promoter (Reynolds et al., 2000).
This treatment abolished the capacity of lung to recon-
stitute the bronchiolar and alveolar epithelia, indicating
that Clara cell progenitors are essential for the mainte-
nance of these epithelia (Figure 1). In contrast, bron-
chial epithelium, including Clara cells, was reconstitu-
ted from a basal cell population expressing keratin 14,
indicating that these basal cells can differentiate into
Clara cells in the proximal airway epithelium (Hong et
al., 2004), but not in terminal bronchioles or alveoli.
When mice are exposed to the lung-damaging agent
naphthalene, a different scenario is observed. In this
case, nearly all Clara cells lining the bronchial surface
and terminal bronchioles are ablated. In two regions,
however, cells expressing Clara specific markers sur-
vive. Surviving Clara cells were found in neuroepithelial
bodies, structures that replenish both neuroendocrine
cell and Clara cell populations (Reynolds et al., 2000).
However, given the limited location and frequency of
neuroepithelial bodies, these structures are likely to be
only minor players in terminal bronchiolar repair. Surviv-
ing Clara cells that express both Clara-specific and al-
veolar-specific markers were also found at the bronchi-
oalveolar duct junction (Giangreco et al., 2002). These
regional-specific stem cells appear crucial for the re-
generation of epithelial components (Clara cells and al-
veolar cells) of the terminal bronchioles and alveoli. The
obvious question then is whether any of these stem cell
niches are involved in lung cancer. This is the question
that Kim et al. (2005) address in this issue of Cell. These
authors investigate in vitro and in vivo whether any of
the cells at the bronchioalveolar duct junction exhibit
features of stem cells. They discovered that cells at this
junction carrying Clara cell and alveolar-cell markers
appear refractory to naphthalene treatment and start to
divide after naphthalene-induced damage, resulting in
repair of damaged lung epithelial tissue. This suggests
that these double-positive cells are precursors of both
Clara cells and alveolar type I and type II cells. More
importantly, these double-positive cells appear enriched
in FACS-sorted Sca-1pos/CD34pos cell populations and
show enhanced capacity for both self-renewal and dif-
ferentiation in vitro. Upon plating in Matrigel, these
double-positive cells give rise to both Clara cells and
alveolar cells, indicating that they are indeed progeni-
tors of both cell types. Thus, Kim and coworkers call
these cells bronchioalveolar stem cells (Kim et al.,
2005; Figure 1).
Expression of the oncogenic protein K-ras by these
bronchioalveolar stem cells, either in vitro or in vivo
(Jackson et al., 2001), boosted their proliferation. Such
a response was not seen in cultured alveolar cells. This
finding is in keeping with the observation that K-ras ex-
pression in lung tissue causes proliferation of only a
small fraction of lung epithelial cells (Guerra et al. 2003).
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812Figure 1. A Critical Role for Bronchioalveolar Stem Cells in Lung Homeostasis and Tumorigenesis
Depicted is a bronchiole harboring neuroendocrine bodies (NEB) that contain pulmonary neuroendocrine cells and variant (v) Clara cells.
Variant Clara cells that express both Clara-specific and alveolar-specific markers are also found at the bronchioalveolar duct junction (BADJ).
These cells are bronchioalveolar stem cells (BASCs). They are refractory to the lung-damaging agent naphthalene and are capable of repopu-
lating the terminal bronchioles and alveolar surface with Clara cells and alveolar type II and type I cells after lung damage. Notably, naphtha-
lene treatment of conditional K-ras mice (in which K-ras is switched on by AdenoCre) induces enhanced proliferation of BASCs. FACS sorting
of dissociated lung cells using general stem cell markers (Sca-1 and CD34) allowed enrichment of BASCs with the capacity for enhanced
proliferation. Although activation of K-ras resulted in enhanced proliferation of BASCs, it does not stimulate proliferation of lung alveolar cells.
Single BASCs give rise to colonies containing Clara cells and alveolar cells type I and II, illustrating the multipotent nature of these lung stem
cells. Presumably, accumulation of mutations in BASCs results in the emergence of CSCs, although this has not yet been demonstrated.Furthermore, when the AdenoCre construct was used t
ato induce tumorigenesis in naphthalene-treated mice
expressing K-ras conditionally, there was an increase t
ain the number and size of tumors. Such tumors ex-
pressed the alveolar-specific SP-C marker, a predomi- s
fnant differentiation marker that was also frequently ex-
pressed by the double-positive bronchioalveolar stem o
dcells after these cells were induced to express K-ras.
This finding implicates these double-positive cells with s
mtheir stem cell-like features in the transformation of nor-
mal lung epithelia into adenocarcinomas. As these lung p
nstem cells are already endowed with the capacity for
self-renewal, they are excellent candidates for the ac-
bcumulation of deleterious mutations. The finding that
larger tumors arise after naphthalene treatment points l
vto the possibility that microenvironmental conditions
may work synergistically with activated K-ras to pro- t
vmote tumorigenesis, in keeping with the classical initia-
tion-promotion model of tumor formation. o
tThe Kim et al. (2005) findings are an important ad-
vance as they provide us with a candidate target cell v
tfrom which nonsmall cell lung cancers may arise. Fur-
thermore, the development of in vitro methods to purify, r
opropagate, and differentiate lung stem cells offers ex-
citing opportunities for follow-up studies. Obviously, vhere are many questions still to be answered. For ex-
mple, do these bronchioalveolar stem cells give rise
o CSCs and, if so, which mutations are required to
chieve this transformation? We eagerly await the re-
ults of serial grafting experiments with cells enriched
or bronchioalveolar stem cell markers or with bronchi-
alveolar stem cells carrying different mutations intro-
uced in vitro. Surprisingly, although bronchioalveolar
tem cells from mouse lung can be propagated for
any generations on feeder-cell layers in vitro, it has
roved difficult to establish cell lines from adenocarci-
omas induced in the same mice.
The mouse model of lung tumorigenesis described
y Kim et al. (2005) provides us with a system that al-
ows the study of how nonsmall cell lung cancers de-
elop with high precision. Learning the Achilles heel of
hese stem cells might help us to design better inter-
ention strategies for treating human lung cancer. This
ptimism is supported by the promising response to
he drug Iressa of lung cancer patients, who carry acti-
ating mutations in the epidermal growth factor recep-
or (Paez et al., 2004). The work of Kim and colleagues
epresents not only a leap forward in our understanding
f lung tumorigenesis, it also heralds the arrival of a
aluable mouse model for identifying those cells that
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813should be the targets of therapeutic intervention. Some
of the more notorious critics of mouse tumor models
might start thinking about lowering their collective
voices.
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